Sonu Abraham, MD
Advanced Heart Failure and Transplant Cardiology · Lexington, KYNPI 1164975835
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,500 of the $12,834 with a category attached, or 81.8%. Abbott accounts for 88.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $10,690 and has fallen 93.4% since, to $711 in 2025.
Across 49 payments — averaging $261.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Astellas Pharma US Inc$298
- Cvrx, Inc.$180
- AstraZeneca$167
- E.r. Squibb & Sons, L.L.C.$154
- Scpharmaceuticals Inc.$121
- plus $552 from 12 others
What the payments were for
- Grants$10,50082%
- Food & beverage$1,72913%
- Education$6045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $11,361 |
| Astellas Pharma US Inc | 3 | $298 |
| Cvrx, Inc. | 3 | $180 |
| AstraZeneca(2 entities) | 8 | $167 |
| E.r. Squibb & Sons, L.L.C. | 3 | $154 |
| Scpharmaceuticals Inc. | 1 | $121 |
| Boehringer Ingelheim | 2 | $93 |
| Gilead | 4 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $75 |
| Medtronic | 1 | $70 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Bayer | 1 | $28 |
| Merck | 2 | $23 |
| Biogen | 1 | $21 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$274
- ENSITE$161
- CARDIOMEMS$141
- CAMZYOS$124
- FUROSCIX$121
- Barostim Neo System$114
How this compares
Too few advanced heart failure and transplant cardiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 19 | $174 |
| Spironolactone | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Lexington
- Marciano LeeLexington$11K
- Andrew KolodziejLexington$7K
- Navin RajagopalanLexington$6K
- Maya IgnaszewskiLexington$6K
- Paul AnayaLexington$194
- Timothy RaymondFt Wright$88K
- Chioma ObiokoyeLouisville$14K
- Hareeprasad VongooruEdgewood$8K
- Amaninderapal GhotraEdgewood$8K
- Keerthy NarisettyEdgewood$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.